^
    Back
    Association details:
    Biomarker:Chr t(11;14)
    Cancer:Multiple Myeloma
    Drug:pomalidomide (TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

    Published date:
    11/04/2021
    Excerpt:
    From the overall cohort, patients with t(11;14) MM receiving pomalidomide + dexamethasone (PomDex) in ≥3rd line were selected...A PR or better was observed in 34% of patients with PomDex.
    Secondary therapy:
    dexamethasone
    DOI:
    10.1182/blood-2021-149336